Join us for our first Leadership Q&A of 2025, featuring Dr. JP Clancy, and the potential impact of Alyftrek on the CF community. He will also share details about how theratyping is paving the way for broader access to modulator therapies, opening up treatment options for more mutations. This is a unique opportunity to hear from a leading expert in the field and gain valuable insights into the future of CF research.
